Global Agitation in Delirium Management Market, By Drug Type (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Route of Administration (Oral, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 237.2 Mn in 2023 and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on the adoption of growth strategies, such as product approvals, which is expected to drive the global agitation in delirium management market’s growth. For instance, in December 2020, Aurobindo Pharma, a pharmaceutical company, received approval from the U.S. Food and Drug Administration to manufacture and market Dexmedetomidine Hydrochloride in 0.9% sodium chloride injection, 200 g/50 mL, and 400 g/100 mL single-dose flexible containers.
Global Agitation in Delirium Management Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly and has a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
According to the research carried out by researchers from the Universitat Oberta de Catalunya (UOC), published in the Journal of Clinical Immunology and Immunotherapy in November 2020, symptoms like fever and increased invasive mechanical ventilation during COVID-19 increase the risk of delirium. According to the same source, the researchers also found that coronavirus disease not only damages the lungs and other organs such as the kidneys and heart but also affects the central nervous system. It produces neurocognitive alterations such as headaches, delirium, and psychotic episodes in COVID-19 patients.
Thus, the researchers provided three hypotheses in order to explain how the coronavirus affects the central nervous system, which can lead to delirium in COVID-19 patients which is due to: hypoxia or neuronal oxygen deficiency; inflammation of the brain tissue due to cytokine storm; and the ability of the virus to cross the blood-brain barrier which directly affects the brain.
Global Agitation in Delirium Management Market: Key Developments
In October 2020, BioXcel Therapeutics, Inc., a biopharmaceutical company, got authorization for its Investigational New Drug (IND) request for BXCL501 from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA). The expected permission is for the management of agitation related to delirium, and presently it’s under Phase 2 of the clinical trial.
Browse 35 Market Data Tables and 31 Figures spread through 170 Pages and in-depth TOC on “Global Agitation in Delirium Management Market”- Forecast to 2030, Global Agitation in Delirium Management Market, By Drug Type (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Route of Administration (Oral, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/agitation-in-delirium-management-market-4430
Key Takeaways of the Global Agitation in Delirium Management Market:
- The global agitation in delirium management market is expected to exhibit a CAGR of 4.6% during the forecast period. The merger with emerging economies such as China offers lucrative growth opportunities for players in the global agitation in delirium management market.
- Among route of administration, the oral segment is expected to hold a dominant position due to increasing research and development for oral antiphyscotic drugs in the global agitation in delirium management market during the forecast period. For instance, according to data published by the American College of Physicians (ACP) Journal on September 5, 2023, a cohort study was conducted for the comparative safety analysis of oral antipsychotics for in-hospital adverse clinical events in older adults after major surgery. The study results suggest that atypical antipsychotics and haloperidol have similar rates of in-hospital adverse clinical events in older patients with postoperative delirium who receive an oral low-to-moderate dose antipsychotic drug.
- Among regions, North America is expected to be the dominant region in the global agitation in delirium management market, owing to increasing product approval by regulatory authorities. For instance, on March 6, 2023, according to the data published by the Parkinson's Foundation, a non-profit organization, Parkinson’s disease was the second most common age-related neurodegenerative condition diagnosed in North America. In late 2022, a Parkinson’s Foundation-backed study revealed that nearly 90,000 people are diagnosed with PD every year in the U.S., a 50% increase from the previously estimated rate of 60,000 diagnoses annually.
- Major players operating in the global agitation in delirium management market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited
